These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29099417)

  • 41. Protective effects of calcyclin-binding protein against pulmonary vascular remodeling in flow-associated pulmonary arterial hypertension.
    Zhou J; Li F; Yang Y
    Respir Res; 2022 Aug; 23(1):223. PubMed ID: 36042446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Siah-1S, a novel splice variant of Siah-1 (seven in absentia homolog), counteracts Siah-1-mediated downregulation of beta-catenin.
    Mei Y; Xie C; Xie W; Wu Z; Wu M
    Oncogene; 2007 Sep; 26(43):6319-31. PubMed ID: 17420721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma.
    Zhao M; Zhang RZ; Qi DW; Chen HY; Zhang GC
    Exp Ther Med; 2020 Aug; 20(2):1397-1404. PubMed ID: 32742374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses.
    Matsuzawa SI; Reed JC
    Mol Cell; 2001 May; 7(5):915-26. PubMed ID: 11389839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of the CacyBP/SIP protein in gastric cancer.
    Zhai H; Meng J; Jin H; Li Y; Wang J
    Oncol Lett; 2015 May; 9(5):2031-2035. PubMed ID: 26137007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint.
    Fukushima T; Zapata JM; Singha NC; Thomas M; Kress CL; Krajewska M; Krajewski S; Ronai Z; Reed JC; Matsuzawa S
    Immunity; 2006 Jan; 24(1):29-39. PubMed ID: 16413921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MAP kinase p38 is a novel target of CacyBP/SIP phosphatase.
    Topolska-Woś AM; Rosińska S; Filipek A
    Amino Acids; 2017 Jun; 49(6):1069-1076. PubMed ID: 28283909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RACK1 suppresses gastric tumorigenesis by stabilizing the β-catenin destruction complex.
    Deng YZ; Yao F; Li JJ; Mao ZF; Hu PT; Long LY; Li G; Ji XD; Shi S; Guan DX; Feng YY; Cui L; Li DS; Liu Y; Du X; Guo MZ; Xu LY; Li EM; Wang HY; Xie D
    Gastroenterology; 2012 Apr; 142(4):812-823.e15. PubMed ID: 22240482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ERK1/2 is dephosphorylated by a novel phosphatase--CacyBP/SIP.
    Kilanczyk E; Filipek S; Filipek A
    Biochem Biophys Res Commun; 2011 Jan; 404(1):179-83. PubMed ID: 21110948
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Up-regulation of CacyBP/SIP during rat breast cancer development.
    Kilańczyk E; Gwoździński K; Wilczek E; Filipek A
    Breast Cancer; 2014 May; 21(3):350-7. PubMed ID: 22926504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Newcastle Disease Virus V Protein Inhibits Cell Apoptosis and Promotes Viral Replication by Targeting CacyBP/SIP.
    Chu Z; Wang C; Tang Q; Shi X; Gao X; Ma J; Lu K; Han Q; Jia Y; Wang X; Adam FEA; Liu H; Xiao S; Wang X; Yang Z
    Front Cell Infect Microbiol; 2018; 8():304. PubMed ID: 30234028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2.
    Chen X; Zheng P; Xue Z; Li J; Wang W; Chen X; Xie F; Yu Z; Ouyang X
    Apoptosis; 2013 Jul; 18(7):861-9. PubMed ID: 23463283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma.
    Wang J; Zhang X; Ma X; Chen D; Cai M; Xiao L; Li J; Huang Z; Huang Y; Lian Y
    J Exp Clin Cancer Res; 2023 Nov; 42(1):303. PubMed ID: 37968706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inactivating mutations of the Siah-1 gene in gastric cancer.
    Kim CJ; Cho YG; Park CH; Jeong SW; Nam SW; Kim SY; Lee SH; Yoo NJ; Lee JY; Park WS
    Oncogene; 2004 Nov; 23(53):8591-6. PubMed ID: 15467739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-dependent changes in neuronal distribution of CacyBP/SIP: comparison to tubulin and the tau protein.
    Filipek A; Schneider G; Mietelska A; Figiel I; Niewiadomska G
    J Neural Transm (Vienna); 2008 Sep; 115(9):1257-64. PubMed ID: 18506390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between CacyBP/SIP expression and prognosis in astrocytoma.
    Zhao W; Wang C; Wang J; Ge A; Li Y; Li W; Lu Y
    J Clin Neurosci; 2011 Sep; 18(9):1240-4. PubMed ID: 21764585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CacyBP/SIP expression is involved in the clinical progression of breast cancer.
    Wang N; Ma Q; Wang Y; Ma G; Zhai H
    World J Surg; 2010 Nov; 34(11):2545-52. PubMed ID: 20585948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct effect of CacyBP/SIP on the ERK1/2-CREB-BDNF pathway in undifferentiated and differentiated neuroblastoma NB2a cells.
    Rosińska S; Leśniak W; Filipek A
    Neurochem Int; 2016 Jul; 97():65-72. PubMed ID: 27180052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of β-catenin.
    Rines AK; Burke MA; Fernandez RP; Volpert OV; Ardehali H
    FASEB J; 2012 Nov; 26(11):4685-95. PubMed ID: 22874833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. S100A4 negatively regulates β-catenin by inducing the Egr-1-PTEN-Akt-GSK3β degradation pathway.
    Yang W; Nam K; Ju JH; Lee KM; Oh S; Shin I
    Cell Signal; 2014 Oct; 26(10):2096-106. PubMed ID: 24975844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.